Patients with metastatic soft-tissue sarcoma can benefit from systemic therapy, but the best drug combinations for the different disease subtypes remain to be established. Recently, great emphasis has been placed on histology-based chemotherapy regimens. Herein, we discuss the results of a recently published study demonstrating that some of these regimens are not superior to standard-of-care chemotherapy in the neoadjuvant setting.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Noujaim, J., Thway, K., Sheri, A., Keller, C. & Jones, R. L. Histology-driven therapy: the importance of diagnostic accuracy in guiding systemic therapy of soft tissue tumors. Int. J. Surg. Pathol. 24, 5–15 (2016).
[No authors listed] Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-Analysis Collaboration. Lancet 350, 1647–1654 (1997).
Pervaiz, N. et al. A systematic met-analysis of randomized controlled trials for adjuvant chemotherapy for localized resectable soft tissue sarcoma. Cancer 113, 573–581 (2008).
Woll, P. J. et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 13, 1045–1054 (2012).
Gortzak, E. et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer 37, 1096–1103 (2001).
Gronchi, A. et al. Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 18, 812–822 (2017).
Stacchiotti, S. et al. High-grade soft-tissue sarcomas: tumor response assessment — pilot study to assess the correlation between radiologic and pathologic response by using RECIST and Choi criteria. Radiology 251, 447–456 (2009).
Wardelmann, E. et al. Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG) recommendations for pathological examination and reporting. Eur. J. Cancer 53, 84–95 (2016).
Whitehead, J., Todd, S. & Hall, W. J. Confidence intervals for secondary parameters following a sequential test. J. Roy. Statist. Society Soc. B. 62, 731–745 (2000).
Acknowledgements
The authors acknowledge support from the NIHR Royal Marsden/ICR Biomedical Research Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.L.J. has acted as a consultant for Pharmamar. K.T. declares no competing interests.
Rights and permissions
About this article
Cite this article
Jones, R., Thway, K. Does histotype-tailored neoadjuvant therapy improve outcomes?. Nat Rev Clin Oncol 14, 589–590 (2017). https://doi.org/10.1038/nrclinonc.2017.118
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.118
